Vantage logo

Ipsen’s quick fix backfires

A failed phase III trial has Ipsen clutching at straws to salvage its rare bone disease project palovarotene, which it bought for $1bn a mere 11 months ago.

Vantage logo

Forty Seven bucks the trend

Tackling the CD47 pathway has seen off several industry players, but Forty Seven continues proudly flying the flag.

Vantage logo
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.